China Sxt Pharmaceuticals Stock Buy Hold or Sell Recommendation
| SXTC Stock | USD 2.82 0.04 1.44% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding China SXT Pharmaceuticals is 'Hold'. Macroaxis provides China SXT buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SXTC positions.
Check out China SXT Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as China and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
China |
Execute China SXT Buy or Sell Advice
The China recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on China SXT Pharmaceuticals. Macroaxis does not own or have any residual interests in China SXT Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute China SXT's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Insignificant | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
China SXT Trading Alerts and Improvement Suggestions
| China SXT is way too risky over 90 days horizon | |
| China SXT appears to be risky and price may revert if volatility continues | |
| China SXT has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.93 M. Net Loss for the year was (3.1 M) with profit before overhead, payroll, taxes, and interest of 553.97 K. | |
| China SXT Pharmaceuticals currently holds about 15.52 M in cash with (1.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| China SXT has a frail financial position based on the latest SEC disclosures |
China SXT Returns Distribution Density
The distribution of China SXT's historical returns is an attempt to chart the uncertainty of China SXT's future price movements. The chart of the probability distribution of China SXT daily returns describes the distribution of returns around its average expected value. We use China SXT Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of China SXT returns is essential to provide solid investment advice for China SXT.
| Mean Return | 1.22 | Value At Risk | -10.88 | Potential Upside | 15.34 | Standard Deviation | 20.21 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of China SXT historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
China Stock Institutional Investors
| Shares | Bank Of Montreal | 2024-12-31 | 10 K | Bmo Capital Markets Corp. | 2024-12-31 | 10 K | Ubs Group Ag | 2024-12-31 | 8.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Gsa Capital Partners Llp | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Baader Bank Inc | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
China SXT Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 38.6K | (180.8K) | 409.0K | (190.3K) | (171.3K) | (162.7K) | |
| Change In Cash | 6.1M | 2.2M | 1.8M | (5.3M) | (4.8M) | (4.5M) | |
| Net Borrowings | 2.6M | 5.6M | 12.4M | (1.0M) | (1.2M) | (1.1M) | |
| Free Cash Flow | (1.4M) | 205.8K | (151.4K) | (1.9M) | (1.7M) | (1.7M) | |
| Depreciation | 345.4K | 320.0K | 250.2K | 203.2K | 233.7K | 238.2K | |
| Other Non Cash Items | 1.6M | 1.1M | 408.7K | 996.7K | 897.0K | 918.9K | |
| Capital Expenditures | 93.0K | 62.5K | 70.7K | 7.1K | 6.4K | 6.0K | |
| Net Income | (2.7M) | (5.7M) | (5.9M) | (3.1M) | (2.8M) | (2.9M) | |
| End Period Cash Flow | 13.4M | 15.6M | 17.4M | 12.1M | 13.9M | 9.2M | |
| Change To Netincome | 82.3K | 5.5M | 1.6M | 3.8M | 4.3M | 4.5M | |
| Investments | (8.8M) | (46.9K) | (12.3K) | 26.4K | 30.4K | 31.9K |
China SXT Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to China SXT or Personal Care Products sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that China SXT's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a China stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.45 | |
β | Beta against Dow Jones | 2.18 | |
σ | Overall volatility | 20.59 | |
Ir | Information ratio | 0.07 |
China SXT Volatility Alert
China SXT Pharmaceuticals is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure China SXT's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact China SXT's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.China SXT Fundamentals Vs Peers
Comparing China SXT's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze China SXT's direct or indirect competition across all of the common fundamentals between China SXT and the related equities. This way, we can detect undervalued stocks with similar characteristics as China SXT or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of China SXT's fundamental indicators could also be used in its relative valuation, which is a method of valuing China SXT by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare China SXT to competition |
| Fundamentals | China SXT | Peer Average |
| Return On Equity | -0.22 | -0.31 |
| Return On Asset | -0.0497 | -0.14 |
| Profit Margin | (1.61) % | (1.27) % |
| Operating Margin | 7.34 % | (5.51) % |
| Current Valuation | (7.99 M) | 16.62 B |
| Shares Outstanding | 507.8 K | 571.82 M |
| Shares Owned By Insiders | 3.16 % | 10.09 % |
| Shares Owned By Institutions | 0.10 % | 39.21 % |
| Number Of Shares Shorted | 37.78 K | 4.71 M |
| Price To Earning | 5.73 X | 28.72 X |
| Price To Book | 0.10 X | 9.51 X |
| Price To Sales | 0.74 X | 11.42 X |
| Revenue | 1.93 M | 9.43 B |
| Gross Profit | 553.97 K | 27.38 B |
| EBITDA | (2.35 M) | 3.9 B |
| Net Income | (3.1 M) | 570.98 M |
| Cash And Equivalents | 15.52 M | 2.7 B |
| Cash Per Share | 5.78 X | 5.01 X |
| Total Debt | 2.65 M | 5.32 B |
| Debt To Equity | 0.68 % | 48.70 % |
| Current Ratio | 1.31 X | 2.16 X |
| Book Value Per Share | 50.24 X | 1.93 K |
| Cash Flow From Operations | (1.93 M) | 971.22 M |
| Short Ratio | 0.28 X | 4.00 X |
| Earnings Per Share | (28.58) X | 3.12 X |
| Number Of Employees | 75 | 18.84 K |
| Beta | 1.12 | -0.15 |
| Market Capitalization | 1.43 M | 19.03 B |
| Total Asset | 23.13 M | 29.47 B |
| Retained Earnings | (24.71 M) | 9.33 B |
| Working Capital | 5.33 M | 1.48 B |
| Net Asset | 23.13 M |
China SXT Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as China . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About China SXT Buy or Sell Advice
When is the right time to buy or sell China SXT Pharmaceuticals? Buying financial instruments such as China Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having China SXT in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Basic Utilities Thematic Idea Now
Basic Utilities
Companies involved in production and distribution of electric, gas, water, and other energy utilities. The Basic Utilities theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Basic Utilities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out China SXT Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (28.58) | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.